SubsidieMeestersAn innovative implantable device and management platform to prevent chronic fluid congestion
FILBERT is an implantable peritoneal ultrafiltration system that enables continuous fluid management for diuretic-resistant CHF patients, improving quality of life and reducing healthcare costs.
Projectdetails
Introduction
Pathologic fluid overload is a main clinical complication of congestive heart failure (CHF). CHF is a severe chronic disease affecting approximately 28 million people worldwide.
Patient Challenges
Around 8 million CHF patients are resistant to oral medications and undergo frequent hospitalizations to remove extra fluids with aggressive acute treatments, all carrying severe complications. None of these treatments can prevent fluid accumulation.
Innovation by Paragate Medical
The Israeli SME Paragate Medical has developed FILBERT, a unique implantable peritoneal ultrafiltration system for diuretic-resistant CHF patients.
Key Features of FILBERT
- Enables 24/7 monitoring and gentle draining of extra fluids in the urinary system, preventing their accumulation.
- A remote treatment management platform allows physicians to continuously control patients’ conditions and timely adjust therapy to prevent fluid accumulation.
Impact on Healthcare
FILBERT shifts the paradigm of fluid congestion care from the hospital to the home, improving patients’ quality of life and saving billions for healthcare systems.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 3.994.993 |
Tijdlijn
| Startdatum | 1-8-2023 |
| Einddatum | 31-7-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- PARAGATE MEDICAL LTDpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
The first heart failure therapy management point-of-care device with multiplex and multimodal sensorCardioCap is a handheld POC device that uses a finger-prick blood sample to simultaneously assess heart failure severity through four biomarkers, aiming to reduce re-hospitalization and mortality rates by 30%. | EIC Accelerator | € 2.499.999 | 2025 | Details |
Development and clinical evaluation of an end-to-end Heart Failure management solution powered by predictive AIImplicity is developing an AI-driven platform to predict heart failure events using cardiac device data, enhancing patient care and reducing hospitalizations through tailored insights and management tools. | EIC Accelerator | € 2.488.359 | 2025 | Details |
ContraBand: the only heart failure medical device that is placed outside the heartContraBand is an implantable device designed to restore heart function in CHF patients, aiming for a 2024 launch and generating significant revenue while creating over 95 jobs in Europe. | EIC Accelerator | € 2.499.999 | 2022 | Details |
Saving patients from severe heart failureThe ICOMS FlowMaker® is a novel intracardiac assist device designed to improve the quality of life for severe heart failure patients, aiming for EU market entry by 2026 through clinical trials. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Transcatheter Ventricular Repair Device for treatment of Heart Failure PatientsCardiac Success aims to develop the V-sling, a transcatheter device to enhance heart function in heart failure patients, through product optimization and pre-clinical testing. | EIC Accelerator | € 2.500.000 | 2022 | Details |
The first heart failure therapy management point-of-care device with multiplex and multimodal sensor
CardioCap is a handheld POC device that uses a finger-prick blood sample to simultaneously assess heart failure severity through four biomarkers, aiming to reduce re-hospitalization and mortality rates by 30%.
Development and clinical evaluation of an end-to-end Heart Failure management solution powered by predictive AI
Implicity is developing an AI-driven platform to predict heart failure events using cardiac device data, enhancing patient care and reducing hospitalizations through tailored insights and management tools.
ContraBand: the only heart failure medical device that is placed outside the heart
ContraBand is an implantable device designed to restore heart function in CHF patients, aiming for a 2024 launch and generating significant revenue while creating over 95 jobs in Europe.
Saving patients from severe heart failure
The ICOMS FlowMaker® is a novel intracardiac assist device designed to improve the quality of life for severe heart failure patients, aiming for EU market entry by 2026 through clinical trials.
Transcatheter Ventricular Repair Device for treatment of Heart Failure Patients
Cardiac Success aims to develop the V-sling, a transcatheter device to enhance heart function in heart failure patients, through product optimization and pre-clinical testing.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Acute Heart FailureHet project richt zich op het ontwikkelen van een platform voor real-time meting van urine-biomarkers bij acuut hartfalen. | 1.1 - Onderz... | € 598.145 | 2023 | Details |
Novel microsensing platform for remote patient monitoringThe FORESEE project aims to advance implantable microstimulators for remote monitoring of chronic heart failure, enhancing patient care and market access for 10.5 million potential users. | EIC Transition | € 2.499.051 | 2023 | Details |
Boost of DiureticsHet project ontwikkelt een goedkope en effectieve methode voor thuismonitoring van hart- en longfalen, gericht op het tijdig signaleren van verslechtering om zorglasten te verlichten. | Mkb-innovati... | € 20.000 | 2020 | Details |
HeartGuard: Thuismonitoring van patiënt met hartfalen halveert aantal ziekenhuisopnamenHeartGuard ontwikkelt een thuismonitoringsysteem voor hartfalen, wat ziekenhuisopnames met 44% kan verminderen. | Mkb-innovati... | € 332.500 | 2023 | Details |
INPUT - OUTPUT DRINKBEKERSHet project ontwikkelt een "Drinkbeker" en polsbandje om de vochtinname van ouderen te monitoren via een app, ter preventie van complicaties door uitdroging. | Mkb-innovati... | € 20.000 | 2020 | Details |
Acute Heart Failure
Het project richt zich op het ontwikkelen van een platform voor real-time meting van urine-biomarkers bij acuut hartfalen.
Novel microsensing platform for remote patient monitoring
The FORESEE project aims to advance implantable microstimulators for remote monitoring of chronic heart failure, enhancing patient care and market access for 10.5 million potential users.
Boost of Diuretics
Het project ontwikkelt een goedkope en effectieve methode voor thuismonitoring van hart- en longfalen, gericht op het tijdig signaleren van verslechtering om zorglasten te verlichten.
HeartGuard: Thuismonitoring van patiënt met hartfalen halveert aantal ziekenhuisopnamen
HeartGuard ontwikkelt een thuismonitoringsysteem voor hartfalen, wat ziekenhuisopnames met 44% kan verminderen.
INPUT - OUTPUT DRINKBEKERS
Het project ontwikkelt een "Drinkbeker" en polsbandje om de vochtinname van ouderen te monitoren via een app, ter preventie van complicaties door uitdroging.